Recombinant Shingles Vaccine Tied to 5.8-Point Absolute Drop in Four-Year Dementia Incidence Among Nursing Facility Residents

The study analyzed claims and electronic records from more than 5,500 facilities between 2017 and 2022, restricting to individuals without prior dementia who were eligible for vaccination. Only 8,843 participants received RZV. Researchers applied target trial emulation to approximate randomized conditions, adjusting for age, comorbidities, and healthcare utilization. Vaccinated residents remained 24% less likely to receive a dementia diagnosis after these adjustments. The absolute risk reduction translated to one dementia case potentially averted for every 17 vaccinated individuals.

This finding extends prior observational work on the older live-attenuated zoster vaccine by focusing exclusively on the recombinant formulation in a frail population. Earlier studies in general older adult cohorts reported similar relative reductions, yet residual healthy-user bias persisted. Here the clinical trigger of facility admission provided a natural point for comparison, and the narrow age and health-status range reduced some confounding. Policy discussions on routine vaccination rarely incorporate potential neuroprotective effects despite their population-level scale.

Remaining questions center on mechanism and causality. Varicella-zoster reactivation may contribute to neuroinflammation, but direct antiviral or adjuvant effects of RZV require testing. Industry funding from GSK was disclosed with no role in design or publication decisions. Next steps include prospective randomized trials that measure incident dementia via standardized cognitive batteries rather than claims diagnoses and that track both two-dose completion rates and long-term outcomes beyond four years.